Pricing Log in Create free account
Friday 6 November 2026 Export ELAN’s income statement to Excel — free account

Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue
+11.3%
EPS
+157.1%
Free cash flow
+35.6%
Total debt
−6.91%

Quarter to September 2026, against a year earlier

23.74 1.57 −6.20%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
161×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Elanco Animal Health Incorporated (ELAN) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Elanco Animal Health Incorporated (ELAN) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 0.0× (September 2018) to 7.2× (October 2020); the current reading is higher than 38% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.1× 40.76%
FY2024 2.2× (22.51%)
FY2023 2.9× 9.46%
FY2022 2.6× (36.21%)
FY2021 4.1× (30.09%)
FY2020 5.9× 39.69%
FY2019 4.2× 10.04%
FY2018 3.8× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 2.8× (8.95%)
Jun 2026 3.1× (1.22%)
Mar 2026 3.2× 1.39%
Dec 2025 3.1× 5.87%
32 more quarters

Against its own ten years

Low 0.0× High 7.2×
Ten-year median 3.2×
Current reading's percentile 41

EV/Sales against peers

Company EV/Sales
VTRS Viatris Inc. compare 2.3×
HIMS Hims & Hers Health, Inc. compare 2.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.0×
ELAN Elanco Animal Health Incorporated 3.0×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
LNTH Lantheus Holdings, Inc. compare 4.1×
NBIX Neurocrine Biosciences, Inc. compare 4.4×
ALKS Alkermes plc compare 4.7×
KNSA Kiniksa Pharmaceuticals International, plc compare 6.7×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ELAN